Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Galapagos NV GLPG announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).
The analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1 preferential inhibitor, in patients who did not respond at week 10.
Additionally, treatment with filgotinib 200mg resulted in clinically meaningful improvements in health-related quality of life (HRQoL) measures by week 58.
The data will be presented at the UEGW virtual 2021 congress.
A post-hoc analysis of the SELECTION study showed that continuous filgotinib 200mg among non-responders resulted in 65.7% biologic-naïve and 62.2% biologic-experienced patients achieving partial Mayo Clinic Score (pMCS) response by Week 12.
17.1% biologic-naïve and 16.7% biologic-experienced patients in pMCS remission.
Related: Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease.
Price Action: GLPG stock is down 1.66% at $50.32 during the premarket session on the last check Tuesday.